Tempus Wealth Planning LLC Has $316,000 Stake in Pfizer Inc. (NYSE:PFE)

Tempus Wealth Planning LLC decreased its stake in Pfizer Inc. (NYSE:PFE) by 31.1% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 11,377 shares of the biopharmaceutical company’s stock after selling 5,132 shares during the period. Tempus Wealth Planning LLC’s holdings in Pfizer were worth $316,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of PFE. GoalVest Advisory LLC raised its position in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the last quarter. Creekmur Asset Management LLC bought a new position in Pfizer in the 4th quarter valued at $32,000. Trivant Custom Portfolio Group LLC raised its position in Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares during the last quarter. VisionPoint Advisory Group LLC raised its position in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new position in Pfizer in the 4th quarter valued at $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Morgan Stanley lifted their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets restated an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, June 26th. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus price target of $35.54.

Pfizer Stock Down 0.5 %

PFE stock opened at $27.70 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The stock has a market capitalization of $156.96 billion, a P/E ratio of -461.59, a P/E/G ratio of 1.09 and a beta of 0.69. The business has a 50-day moving average of $28.04 and a 200-day moving average of $27.71. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $37.80.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.23 earnings per share. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.06%. The ex-dividend date is Thursday, July 25th. Pfizer’s dividend payout ratio is currently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.